Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation
about
Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomicsPharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumonWarfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare dataCost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in ChinaNovel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models.Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model.Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor strokeEconomic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature.Impact of patient adherence on the cost-effectiveness of noninvasive tests for the initial diagnosis of Helicobacter pylori infection in the United StatesNovel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis.Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.The hidden costs of anticoagulation in hospitalized patients with non-valvular atrial fibrillation.Novel oral anticoagulants for atrial fibrillation.Target-specific oral anticoagulants: practice issues for the clinician.Genotype-guided coumarin dosing: where are we now and where do we need to go next?Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review.The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence.Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke.Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR.Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System.Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis.
P2860
Q26822796-3226287C-4460-4714-ABBD-9E0CB69F63D5Q27006860-117A9390-1F71-4FC6-ABAE-3EFA197E3F81Q30766944-B6B6BB25-A539-4A45-B98F-D8D8988D40B2Q34374190-087AF23B-D845-4278-95DA-B34E93AA5326Q34692850-BBD47ACD-18D4-46E9-92B7-38E6368EC66CQ34834319-AD9A7B7B-BD84-418B-B321-9AEF943B5028Q35021898-68E4C449-371F-434E-8091-13B928642258Q35890606-AA43D235-5DA3-489B-9CEF-624D0C27C6F4Q36504118-2DC15FEB-846D-4CEA-B90D-4BEFCAC25C2AQ37595758-ECA0D673-AF40-465C-9900-DADEA4B82F5DQ38042441-9DB11949-4CF6-494F-A5AB-E3E2FF27D359Q38061141-E1FB6379-B003-474B-8B2B-AC8000DB72B5Q38078754-43137121-F68D-4B68-A2DD-C47EE9072E6CQ38097972-F90F30EA-298E-46B2-9401-A34895C5AA67Q38114002-B539EAEC-2609-494C-8248-3965FFBF3B4DQ38254246-D3F73802-BB93-45AE-8FF1-CF4933ACEE52Q38321269-B67DED1A-D051-400D-8213-1A9819F29743Q38671676-09898F62-F3FC-4C8E-9733-C1339D87FBE0Q38713953-C854A548-85CB-480B-A54B-583D4B33AC3EQ38750444-2D3F7DDB-172B-4A0A-AB08-640D467830F3Q38777644-FA259536-802B-4035-B5BA-511E30A11806Q40343303-D44B8AC5-6D9F-4CC1-8173-A69C30A51F7AQ40632516-BF48EC29-3375-4313-A48A-E27158BBC38DQ41535274-259882EA-C73A-4E1D-87B9-D8EF5BC53DEDQ42701943-8660EA7E-BFF9-4333-B9D8-2FA541A77F69Q44700478-7DCB323A-65B3-4C5A-832D-534600AC6246Q46008192-E1FC350C-6141-4EC1-ADDF-5CCE6535CDF5Q46304985-F5FC1A5B-B110-4AF3-8731-BBBAD94B61D7Q48690350-0E8A368B-1BEA-4780-A271-65B59806E4E1Q50950032-9255D382-DE91-4B8D-9E58-FE9706FFE2DB
P2860
Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Cost-effectiveness of dabigatr ...... ients with atrial fibrillation
@ast
Cost-effectiveness of dabigatr ...... ients with atrial fibrillation
@en
Cost-effectiveness of dabigatr ...... ients with atrial fibrillation
@nl
type
label
Cost-effectiveness of dabigatr ...... ients with atrial fibrillation
@ast
Cost-effectiveness of dabigatr ...... ients with atrial fibrillation
@en
Cost-effectiveness of dabigatr ...... ients with atrial fibrillation
@nl
prefLabel
Cost-effectiveness of dabigatr ...... ients with atrial fibrillation
@ast
Cost-effectiveness of dabigatr ...... ients with atrial fibrillation
@en
Cost-effectiveness of dabigatr ...... ients with atrial fibrillation
@nl
P2860
P1433
P1476
Cost-effectiveness of dabigatr ...... ients with atrial fibrillation
@en
P2093
Gergory Cheng
Kia K N Tsui
P2860
P304
P356
10.1371/JOURNAL.PONE.0039640
P407
P577
2012-06-22T00:00:00Z